



The Future of Systemic Lupus Erythematosus Diagnosis and Treatment

UT Southwestern
Medical Center

The Future of Systemic Lupus Erythematosus Diagnosis and Treatment

A Discussion with the Experts

Saturday, May 7, 2022
UT Southwestern Medical Center
Department of Internal Medicine: Division of Rheumatic Diseases
Dallas, TX
(RP2205A)

Course Directors

David Karp, M.D., Ph.D.
Chief, Division of Rheumatic Diseases
UT Southwestern Medical Center

Kathryn Dao, M.D.
Associate Professor - Department of Internal Medicine, Division of Rheumatology
UT Southwestern Medical Center

Purpose and Content

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that is difficult to diagnose and challenging to treat. It can involve multiple organ systems, leading to significant reduction in both the quality of life and overall lifespan of affected individuals. Despite published criteria designed for research studies, it remains difficult to recognize patients in practice, especially early in the course of disease. The management of patients is hampered by the lack of modern treatment guidelines and only a few therapies specifically developed for lupus. This symposium, designed for physicians and researchers, will bring SLE experts together to explain, via didactic lecture and case studies, current information on the cause of this mystifying illness, identify the best way to identify patients in practice, and describe the current and future therapies for lupus patients.

Target Audience

This activity is intended for providers in the specialties of:

- Rheumatology
- Nephrology
- Dermatology
- Immunology
- Internal Medicine



The Future of Systemic Lupus Erythematosus Diagnosis and Treatment

Educational Objectives

Upon completion of this activity, participants should be able to:

1. Describe the current knowledge of the pathophysiology of lupus.
2. Identify appropriate criteria and studies to accurately diagnose lupus.
3. Select the most appropriate therapy options for lupus patients, taking into consideration differing organ-specific manifestations of the condition, such as lupus nephritis.
4. Identify opportunities to advance research in lupus.
5. Describe optimal treatment protocols for lupus nephritis.

Educational Methods

Live online activity featuring lectures and interactive Q&A

Accreditation and Credit Designation Statements

The University of Texas Southwestern Medical Center at Dallas is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas Southwestern Medical Center designates this live activity for a maximum of **8.0 AMA PRA Category 1 Credit(s)™**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Texas Southwestern Medical Center certifies that non-physicians will receive an attendance certificate stating that they participated in the activity that was designated for **8.0 AMA PRA Category 1 Credit(s)™**.

Evaluation

Evaluation by questionnaire will address program content, presentation, and possible bias.



The Future of Systemic Lupus Erythematosus Diagnosis and Treatment

Disclosure of Financial Relationships

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), The University of Texas Southwestern Medical Center, Office of Continuing Medical Education (UTSW CME) requires that the content of CME activities and related materials provide balance, independence, objectivity, and scientific rigor. Planning must be free of the influence or control of any ineligible company, and promote improvements or quality in healthcare. In accordance with ACCME's Standards for Integrity and Independence in Accredited Continuing Education, all persons in the position to control the content of an education activity are required to disclose all financial relationships in any amount occurring within the past 24 months with any ineligible company producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. UT Southwestern also considers ineligible those companies producing, marketing, selling, re-selling, or distributing healthcare products in development for future use on patients, such as healthcare product research companies. All reported financial relationships with ineligible companies are reviewed for relevancy and then mitigated through a content review process prior to the activity (where applicable).

The following is a listing of all individuals that contributed to the educational content of this activity and any reported financial relationships within the last 24 months:

NAME	ROLE	RELATIONSHIP	COMPANY
Puneet Bajaj, M.D.	Moderator	None	N/A
Bonnie Bermas, M.D.	Moderator, Peer Reviewer	None	N/A
Ashira D. Blazer, M.D., MSCI	Speaker	Independent Contractor Independent Contractor	GSK Novartis
Eliza Chakravarty, M.D.	Speaker	None	N/A
Megan E. B. Clowse, M.D., MPH	Speaker	Grant or Contract Independent Contractor	Exagen Pfizer UCB
Karen H. Costenbader, M.D., MPH	Speaker	Professional Services Grant or Contract	Neutrolis Astra Zeneca Merck Lilly Janssen Glaxo Smith Kline Merck Gilead Exagen
Kathryn Dao, M.D.	Course Director, Moderator	Independent Contractor	Bristol Myers Squibb Novartis
Lesley Davila, M.D.	Moderator	None	N/A
Candace Feldman, M.D., MPH, Sc.D.	Speaker	Grant or Contract	Pfizer Pharmaceuticals BMS Foundation
Richard Furie, M.D.	Speaker	Professional Services	GlaxoSmithKline Aurinia Pharmaceuticals Genentech AstraZeneca Boehringer-Ingelheim Kezar

The Future of Systemic Lupus Erythematosus Diagnosis and Treatment

NAME	ROLE	RELATIONSHIP	COMPANY
Judith A. James, M.D., Ph.D.	Speaker	Grant or Contract	Novartis GSK Astra Zeneca
Kenneth Kalunian, M.D.	Speaker	None	N/A
David Karp, M.D., Ph.D.	Course Director, Moderator	Grant or Contract	Bristol-Myers Squibb Celgene Glaxo Smith-Kline Genentech Eli Lilly Lupus Therapeutics Biogen PPD
Patti Katz, Ph.D.	Speaker	None	N/A
Alfred Kim, M.D., Ph.D.	Speaker	Grant or Contract Independent Contractor	GlaxoSmithKline Foghorn Therapeutics Alexion Pharmaceuticals Aurinia Pharmaceuticals Exagen Diagnostics GlaxoSmithKline Pfizer
Liz Lightstone, MBBS	Speaker	Independent Contractor	GSK Biogen Novartis BMS Alexion Kezar Astra Zeneca
Joan T. Merrill, M.D.	Speaker	Grant or Contract Independent Contractor	Astra Zeneca Glaxo Smith Kline Bristo Myers Squibb Abbvie Alexion Amgen Astra Zeneca Aurinia BMS EMD Serono Gilead Glaxo Smith Kline Lilly Merck Provention Remegen Sanofi UCB Zenas Genentech



The Future of Systemic Lupus Erythematosus Diagnosis and Treatment

NAME	ROLE	RELATIONSHIP	COMPANY
Chandra Mohan, M.D., Ph.D.	Speaker	Professional Services Financial Support Stock Options Financial Support	Pharmacyclics/AbbVie Equillium Progentec Hope Biosciences
Virginia Pascual, M.D.	Speaker	Grant or Contract Patent Professional Services	Sanofi Astra Zeneca Novartis Sanofi Astra Zeneca
Michelle Petri M.D., MPH	Speaker	Grant or Contract Independent Contractor	AstraZeneca Eli Lilly Exagen GSK Thermofisher Janssen Alexion Amgen AnaptysBio AstraZeneca Aurinia Axdev Emergent Biisolutions Gilead Biosciences GSK IQVIA Janssen Eli Lilly Merck EMD Serono Momenta Pharmaceuticals Sanofi UCB Caribou Biosciences Kira Pharmaceuticals SinoMab Bioscience Biogen MedShr
Andres Quiceno, M.D.	Moderator	None	N/A
Lisa R. Sammaritano, M.D.	Speaker	None	N/A
Blair Solow, M.D.	Moderator	Grant or Contract	Pfizer



The Future of Systemic Lupus Erythematosus Diagnosis and Treatment

Acknowledgments

Educational Grants

The University of Texas Southwestern Medical Center gratefully acknowledges educational grants from the following companies in support of this CME activity:

Aurinia Pharmaceuticals

Exhibitors

The University of Texas Southwestern Medical Center gratefully acknowledges the exhibitors from the following companies in support of this CME activity:

Amgen

AstraZeneca

GSK

General Information

Evaluations and Certificates

Online course evaluations will be available 3-5 business days after the conference. The evaluation is an important tool for assessing the effectiveness of this activity as well as for planning future activities. We value your feedback.

CME and Attendance Certificates will be available online at <http://cme.utsouthwestern.edu> after completion of the online evaluation. An account must be created at cme.utsouthwestern.edu in order to claim/view credit. Instructions are available upon request for creating this profile.

If you have any questions regarding your certificate you may direct them to: cmeregistrations@utsouthwestern.edu

Disclaimer

This CME program or activity has been planned to be well-balanced and objective in discussion of comparative treatment regimens, and allows for the free scientific exchange of ideas. All treatment recommendations in a CME program or activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis. Information and opinions offered by the speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information.